--- title: "Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy?" type: "News" locale: "en" url: "https://longbridge.com/en/news/277609384.md" description: "IDEAYA Biosciences has initiated a Phase 1 trial for IDE034, a bispecific antibody-drug conjugate, marking a significant milestone with a $5 million payment to Biocytogen. This trial aims to enhance treatment for solid tumors through a dual-antigen targeting approach. While the trial adds to IDEAYA's pipeline, it also increases cash burn and execution complexity. The company's shares have risen, yet remain potentially undervalued amidst ongoing losses and high growth expectations. Analysts have varied fair value estimates for IDEAYA, reflecting differing views on its future potential." datetime: "2026-03-03T11:03:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277609384.md) - [en](https://longbridge.com/en/news/277609384.md) - [zh-HK](https://longbridge.com/zh-HK/news/277609384.md) --- # Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy? - IDEAYA Biosciences recently enrolled the first patient in a Phase 1 trial of IDE034, a bispecific TOP1 antibody-drug conjugate targeting co-expressed PTK7 and B7H3 in solid tumors, triggering a US$5.00 million milestone payment to Biocytogen under their Option and License Agreement. - The trial positions IDE034 as a potentially first-in-class asset with a co-expression-based targeting approach and combination plans with IDEAYA’s PARG inhibitor IDE161, aimed at enhancing selectivity and therapeutic impact in hard-to-treat solid cancers. - Next, we’ll explore how IDE034’s first-in-human trial and its dual-antigen design shape IDEAYA Biosciences’ broader investment narrative. Outshine the giants: these 22 early-stage AI stocks could fund your retirement. ## What Is IDEAYA Biosciences' Investment Narrative? For IDEAYA, the big-picture belief is that its precision oncology pipeline can justify today’s valuation despite ongoing losses and a rich price-to-sales multiple. The recent IDE034 first-in-human trial and the US$5.0 million milestone to Biocytogen extend the company’s DNA damage response story and create another potential clinical catalyst alongside existing programs, but they also add to cash burn and execution complexity. Early-stage ADC assets like IDE034 typically take time before generating clinically meaningful data, so the immediate impact on the core thesis is more about reinforcing pipeline breadth than changing the risk-reward balance overnight. The appointment of a seasoned Chief Development Officer and improving loss profile in 2025 help on the execution front, yet unprofitability and high expectations for future growth remain central risks. However, one key execution risk around IDE034 and the broader pipeline is easy to underestimate. IDEAYA Biosciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be. ## Exploring Other Perspectives IDYA 1-Year Stock Price Chart Three Simply Wall St Community fair values span from about US$50 to a very large upper estimate, underlining how differently people see IDEAYA’s potential. Set against the new IDE034 trial and ongoing losses, this spread reflects how much depends on future clinical and partnership outcomes, so it is worth weighing several viewpoints before forming a view. Explore 3 other fair value estimates on IDEAYA Biosciences - why the stock might be worth just $50.06! ## The Verdict Is Yours Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts. - A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. - Our free IDEAYA Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance. ## Contemplating Other Strategies? Opportunities like this don't last. These are today's most promising picks. Check them out now: - Find 45 companies with promising cash flow potential yet trading below their fair value. - Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. - Uncover the next big thing with 30 elite penny stocks that balance risk and reward. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md) ## Related News & Research - [Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing](https://longbridge.com/en/news/277589490.md) - [BUZZ-IDEAYA rises after lung cancer drug combo testing deal with AstraZeneca](https://longbridge.com/en/news/282173989.md) - [Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?](https://longbridge.com/en/news/282581233.md) - [Transgene completes randomisation in phase 2 trial of tg4050](https://longbridge.com/en/news/282509968.md) - [SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial](https://longbridge.com/en/news/282241332.md)